Objective: HIV-infected patients had a higher prevalence of insulin resistance (IR) and risk of diabetes mellitus (DM) than that observed in healthy controls, but there are no data about the current prevalence considering the changes in HIV presentation and the use of newer antiretroviral drugs. Design: Longitudinal study which involved 265 HIV patients without DM, receiving first (nZ71) and advanced lines of antiretroviral therapy (nZ194). Methods: Prevalence of IR according to clinical and anthropometric variables, including dual X-ray absorptiometry (DXA) scan evaluation. IR was defined as homeostasis model assessment of IR R3.8. Incident DM was assessed during the follow-up. Results: First-line patients had a short time of HIV infection, less hepatitis C virus coinfection, and received mainly an efavirenz-based regimen. Overall, the prevalence of IR was 21% (55 patients, 6% in first-line, 27% in pretreated). In a logistic regression analysis, significant associations were found between the waist/hip circumference ratio (RR 10; 95% CI 1.66-16; P!0.01, per unit), and central fat in percentage (RR 1.08; 95% CI 1.01-1.17; PZ0.04, per unit) as evaluated by DXA, and IR. During 770.8 patient-years, DM was diagnosed in 8% (22 patients), mostly in pretreated patients (10 vs 4%; PZ0.1). Thus, the overall rate of incident DM was 2.85 per 100 person-years, mostly in previous IR (10.39 vs 0.82/100 person-years; PZ0.01). Conclusions: A lower prevalence of IR is observed in the current HIV-infected patients with fewer risk factors and receiving newer antiretroviral drugs. IR continues to identify patients at high risk for developing DM in the short term.
Introduction
The introduction of highly active antiretroviral therapy (HAART) has changed the course of HIV infection, increasing life expectancy (1) , but on the other hand making more prevalent diseases such as osteoporosis, neurocognitive impairment, renal disease, and cardiovascular events (2) . Among these associated comorbidities, HIV-infected patients frequently experience metabolic complications such as insulin resistance (IR), increasing the risk of diabetes mellitus (DM) (3) . Rates of DM among HIV-positive patients have been reported to range between 2 and 14% (4, 5, 6) , and in an aging HIV-positive population, the prevalence of DM is expected to continue to increase.
Indeed, from the beginning of the HIV epidemic, and particularly after the introduction of HAART, the prevalence of IR has been reported in up to 35-63% of patients, much higher than in uninfected control populations (6, 7, 8, 9) . IR in HIV patients has been associated with an increased risk of cardiovascular risk and mortality, and particularly with the development of DM, several folds higher in case of IR (5, 6, 7) . This high prevalence in a younger population has been attributed to the presence of additional risk factors, such as HIV itself, vitamin D deficiency, coinfection with hepatitis C virus (HCV), and particularly as a possible adverse effect of different antiretroviral drugs (4, 10, 11, 12, 13) . This fact is particularly important as the HIV therapeutic arsenal continues to change with the development of newer drug classes and agents within existing drug classes, and therefore, the use of drugs with a lower causal role could change the prevalence and consequences of this complication. Drugs such as lopinavir, indinavir, stavudine (d4T), didanosine (ddI), and zidovudine (AZT) have been associated with IR (14, 15) , but their use has markedly decreased during the last years.
Thus, hypothetically, changes in HIV therapy could have a direct repercussion on metabolic alterations, such as IR and DM, avoiding or delaying its emergence in recently treated patients, and decreasing its prevalence in largely pretreated cases. While this is plausible, the mechanisms of dysglycemia appear to be multifactorial, both HAART-dependent and HAART-independent, and there are few data confirming that the use of the current antiretroviral drugs is beneficial to HIV patients in terms of insulinemia or hyperglycemia.
Keeping this idea in mind, we investigated the rate and causes of IR and the risk of developing DM in currently treated HIV-infected patients in two different populations attending our unit: patients receiving advances lines of therapy, and patients in a first-line regimen.
Patients and methods
This was a prospective cohort study of HIV-positive patients consecutively attending our HIV unit between December 2010 and December 2011. The inclusion criteria were that patients must be over 18 years of age and be receiving antiretroviral treatment. Pregnant women, patients with advanced cirrhosis (Child-Pugh class B-C), daily alcohol intake, those receiving therapies that could alter blood glucose or insulin levels (corticosteroids, chemotherapy, or megestrol acetate), or those with a prior diagnosis of DM or receiving hypoglycemic treatments were excluded. Duration of follow-up spanned from inclusion to December 2013. The study was approved by our IRB and all patients gave informed consent.
Variables
At inclusion visit, information was collected from patients' charts and during patient interviews. Variables collected for patients included socio-demographic aspects (age, sex, risk practice for HIV infection), and clinical variables (time of HIV infection, CDC-stage, CD4C nadir, peak HIV RNA level, HCV coinfection, antiretroviral treatment, and current and total time on therapy). Weight, height, and circumferences of waist and hip were measured as previously published. A venous blood sample was drawn after a 12-h overnight fast for determination of HIV-related parameters (CD4C lymphocyte count and HIV load). Also, patients were screened for HCV coinfection (if not available at history), DM (fasting glucose), insulin (immunoassay, Immulite 2000, Siemens Healthcare Diagnostics, NY, USA), and vitamin D status (serum determination of 25 dihydroxyvitamin D) by enzymoimmunoassay (Architect i2000, Abbott Diagnostics). Blood analysis, including fasting glucose, was repeatedly obtained every 3-4 months as part of routine follow-up of the patients. After inclusion visit, a whole-body dual energy X-ray absorptiometry (DEXA) measurement was performed on all study subjects, using a Hologic QDR-4500A (Hologic, Inc., Bedford, MA, USA). The DEXA scans were assessed with a dedicated scanner and technologist. Routine daily quality control and calibration procedures were performed according to recommendations. The DEXA provided determinations in grams and percent fat for total body, body subregions such as trunk, arms, and legs, and a central abdominal region. We calculated the fat mass ratio (FMR) as the ratio of the percentage of the trunk fat mass to the percentage of the lower limb fat mass (percentage of the trunk fat mass/ percentage of the lower limb fat mass) (16 The prevalence of vitamin D deficiency (!20 ng/ml) was 57%. The median duration of HIV infection was 181.5 months, while the cumulative time on HAART was 120.5 months. A total of 141 patients received ART based on non-nucleoside analogs (54%), while 119 (45%) received protease inhibitors (PI).
As expected, there were significant differences in baseline characteristics between first-line and pretreated patients, both in age and risk practices, and naturally in duration of HIV infection or type and time on antiretroviral therapy. Pretreated patients were older, they had a higher prevalence of HCV coinfection (51 vs 11%), and had a higher duration of HIV infection and length of HAART. Noteworthy, no significant difference was observed in mean BMI, or vitamin D deficiency. Likewise, the use of drugs was different, with a predominance of (Table 2) . Nucleoside reverse transcriptase inhibitors (NRTIs) were mainly tenofovir plus emtricitabine, or abacavir plus lamivudine. No patient received therapy with d4T, ddI, or AZT at inclusion, although 72 and 64% of pretreated patients had received AZT or d4T in the previous current regimen. A dual X-ray absorptiometry (DXA) scan was performed a median time of 59 days after inclusion (3-184). Regarding anthropometric measures, patients largely pretreated had a higher waist/hip circumference ratio and greater percentage of fat accumulation in trunk, despite similar kilograms of fat in trunk. Also, FMR was significantly higher in pretreated patients.
Of note, the current use of PI was not associated with a greater percentage of fat accumulation (28.9 vs 29.1; PZ0.4), or FMR (1.33 vs 1.38; PZ0.43). However, cumulative time on HAART including PIs showed a weak but significant correlation with FMR (rZ0.37; P!0.01) and waist/hip ratio (rZ0.21; PZ0.02), and not with trunk fat in grams or percentage.
Insulin resistance
At study entry, fasting glucose was 96.4 mg/dl (88-103), similar in pretreated and first-line patients, and independent of antiretroviral regimen. Mean insulinemia was 12.8 mU/l (3.2-14.8), significantly higher in the group of pretreated patients ( Thus, the prevalence of IR was higher in each age decade ( Fig. 1) , ranging from 5% for !30 years to 30% in patients over 60 years of age. Strikingly, the prevalence was 6% (four patients) in first-line patients, compared with 27% in pretreated patients. In a univariate analysis (Table 3) , IR was related to higher BMI, duration of HIV infection, total time on antiretroviral therapy, HCV coinfection, greater abdominal waist circumference, and increased waist/hip ratio 
Consequences of IR
In a median follow-up of 35.2 months after insulinemia determination (19.7-40.9; 770.8 patient-years on Prevalence of insulin resistance according to line of antiretroviral treatment and age strata. 
Discussion
Our study, in a large cohort of patients in different lines of therapy, shows that the current prevalence of IR is 21%, lower than previously published, which ranged from 35 to 63% (6, 7) . The prevalence in our study was similar to that seen in the general population, although there are significant differences by age, as it has been described in non-HIV controls older than 55-60 years (20) .
More importantly, our study shows that there are two completely different HIV populations in terms of metabolic complications. Thus, the prevalence was 6% in patients receiving a first-line antiretroviral regimen, despite a median ART treatment time O3 years, and that certain antiretroviral drugs may cause IR for short time periods without alterations in body fat (21, 22) . This rate is clearly lower than the 13% described by Palacios et al. in 2006 (23) in a similar population in our country after only a year on HAART and suggests a change in the risk of this complication for HIV patients starting current antiretroviral drugs.
This difference in prevalence could be due to several causes. First, HIV infection itself may influence the occurrence of IR. The mechanisms by which this occurs are not well understood, but if it is known that persistent immune activation and inflammation would contribute to the development of IR (24, 25) . Indeed, in naïve patients, higher CD4C lymphocyte count is associated with a lower evidence of IR (8, 24, 26) . Our current population started therapy with a higher nadir CD4C count and less time of HIV infection, so favoring fewer metabolic alterations.
Second, there are changes in baseline patient characteristics, with fewer of our patients in first line having HCV coinfection. Hepatitis C coinfection has also been shown in some studies (27, 28) , but not all studies (29) , to be associated with DM. In the first study with 1389 naive HIV patients, a relationship was found between coinfection and DM type 2, but not between coinfection and IR (4). In our current analysis, HCV was associated with a higher level of insulinemia and was a predictor of IR in the univariate analysis, albeit it was not related in the multivariate analysis.
But perhaps one of the most important factors to be evaluated is antiretroviral therapy, as it could be modified. Previously, multiple studies have described the relationship between IR and the use of HAART, particularly PIs and some NRTIs. It has been shown that some PIs such as lopinavir or indinavir increase insulinemia in healthy volunteers (22, 30, 31) , although it is debated whether this could be compensated in prolonged treatments (32) . PIs could inhibit proteases responsible for conversion of proinsulin into insulin, as well as protease regulating insulin catabolism, generating a state of hyperinsulinemia and hyperglycemia (33) . Another mechanism of action would be by reduction of the glucose transport mediated by the transporter glucose transporter protein 4 as shown by in vitro tests with drugs including indinavir, amprenavir, nelfinavir, and ritonavir (34, 35, 36, 37, 38) .
An increased risk of IR and DM has also been found to be associated with individual NRTIs, principally the thymidine analogues AZT and d4T that may directly increase lipolysis and consequently cause RI (11, 14, 15, 39, 40, 41) . Among HIV-infected, cumulative exposure to NRTIs O3 years or to Figure 2 Kaplan-Meier estimates of diabetes mellitus during follow-up according to previous insulin resistance diagnosis (HOMA
R3.8).
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www.eje-online.org the NRTI d4T O1 year was associated with HOMA 1.15-fold higher (15, 42) . Recent studies have suggested that genetically associated mitochondrial dysfunction is a major factor in IR and DM in the general population, and therefore, the development of IR and DM could be a result of mitochondrial dysfunction irrespective of whether the underlying cause is genetic or toxicity (27, 43) . Thus, hypothetically, the use of drugs with lower potential metabolic toxicity and not causing mitochondrial alteration as first-line treatment could decrease the risk of IR. Efavirenz, nevirapine, raltegravir, tenofovir, abacavir, and lamivudine have been associated with lower risk of mitochondrial toxicity, and low DM risk (44, 45, 46) . In addition, newer PI, especially atazanavir and darunavir, have been shown to have lower metabolic toxicity and to rarely cause IR (47, 48, 49, 50, 51) , a fact that could even explain the improvement of IR in pretreated patients switching to these drugs, as previously described with atazanavir, efavirenz, or nevirapine (47, 52) . However, the cross-sectional inclusion of our patients precludes us to know whether lower IR found in pretreated patients is due to persistence of this complication or is the result of progressive decrease with the use of new drugs with a lower toxicity.
Our study including abdominal fat by DXA in all patients shows that IR is fundamentally associated with the abdominal fat accumulation/trunk obesity (53, 54) , and not with antiretroviral therapy, HCV coinfection, vitamin D deficiency, CD4C count nadir, or time of HIV infection. In fact, the amount of visceral fat is the main factor for IR and development of diabetes, together with age, in healthy patients, and previous studies linked closely truncal adiposity and increased waist-to-hip ratio with hyperinsulinemia and overt DM (55) . Exposure to HAART may also lead to IR indirectly, through effects on regional body adipose tissue changes, inflammation and adipokine and free fatty acid dysregulation (9, 56) . Indeed, fat abnormalities described in the lipodystrophy syndrome have been linked to IR and development of DM (16, 57) . We observed a relation between cumulative time on HAART and some anthropometric measures, but neither current PI nor cumulative use explained in-depth fat changes and subsequent IR.
It has been observed that the risk of developing DM in HIV-positive patients receiving HAART was fourfold increased in comparison with HIV-negative patients in an observation period of 4 years (27) . In our series, we found a 3-year estimate of 7% of developing DM for patients with IR at inclusion, but time from the onset of IR to DM cannot be clearly established as it is not known how long patients had IR previously. Of note, the observed rate of 2.85 per 100 person-years is slightly higher than that observed in seronegative controls in the MACS cohort (1.4 per 100 person-years), clearly lower to that described in patients receiving HAART before 2005 (4.7 per 100 person-years), and similar to that described in women in the WIHS cohort (2.8) (27, 58) . Surprisingly, the DAD study found a crude incidence of new DM of 4.2 per 1000 person-years during a follow-up of 5.2 years, similar to that described in the Swiss cohort (4.6 per 1000 person-years) (29, 59) . Although race, sex, BMI, and other baseline characteristics such as HAART exposure could be different, both studies are based on a large number of patients in different situations with prolonged exposure. In any case, the rate in our patients without IR receiving HAART, 8.2 per 1000 person-years is more similar to that observed in these large cohorts.
Among the limitations of our study, the most significant is the diagnosis of incident DM by confirmed fasting glucose above 126 mg/dl, and not by oral glucose tolerance test, a fact that could have delayed the time to diagnosis. On the other hand, it reflects the clinical management of patients. Also, information regarding other important risk factors for IR or DM (e.g. family history, physical inactivity) was not collected, but in contrast, no patient received during the study any drugs associated with worsening IR or DM, such as niacin, megestrol acetate, steroids, or thiazides. Finally, follow-up could be not long enough to adequately show the rate of DM, taking into account the influence of aging. However, the previous studies had a similar follow-up, and even longer exposure times with few new cases of DM could lead to a lower incidence rate, as observed in large cohorts.
In conclusion, current prevalence of IR in HIV patients appears to be lower than previously reported, and it is primarily associated with accumulation of abdominal fat, as described in the general population. We found a 3-year estimate risk of 7% for developing DM in patients with IR, supporting the importance of regular screening for hyperglycemia among HIV-infected persons, especially in largely pretreated patients with increased abdominal fat. On the other hand, our study confirms the low risk of IR in recently diagnosed HIV patients receiving current antiretroviral drugs, and it suggests a progressive decrease for this complication in this high-risk population.
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